Multiple Myeloma: Pricing And Reimbursement Challenges Escalate Even As Blockbusters Go Generic
As new drugs move into earlier lines of therapy for use in combination and for longer periods, payers are growing more sensitive to myeloma therapies' costs in the US and major ex-US markets.
You may also be interested in...
A series of abstracts highlight the impact of the ACA and Medicaid expansion on ovarian cancer diagnosis, racial disparities in time to treatment and the impact of insurance type on myeloma survival.
The adaptive trial design will help test smaller subpopulations and could lead to more effective and cost-efficient treatment strategies.
Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal
The latest drug development news and highlights from our US FDA Performance Tracker.